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Abstract
Background and Objective Epidural corticosteroid injec-
tions (ESIs) have been used for several decades and now
represent the most common intervention performed for the
management of back pain with a radicular component.
However, several reports have presented devastating
complications and adverse effects, which fuelled concerns
over the risk versus clinical effectiveness. The authors offer
a comprehensive review of the available literature and
analyse the data derived from studies and case reports.
Methods Studies were identified by searching PubMed
MEDLINE, Ovid MEDLINE, EMBASE, Scopus, Google
Scholar and the Cochrane Library to retrieve all available
relevant articles. Publications from the last 20 years
(September 1994 to September 2014) were considered for
further analysis. Studies selected were English-language
original articles publishing results on complications related
to the technique used for cervical and lumbar ESIs. The
studies had to specify the approach used for injection. All
studies that did not fulfil these eligibility criteria were
excluded from further analysis.
Results Overall, the available literature supports the view
that serious complications following injections of corti-
costeroid suspensions into the cervical and lumbar epidural
space are uncommon, but if they occur they can be
devastating.
Conclusions The true incidence of such complications
remains unclear. Direct vascular injury and/or administra-
tion of injectates intra-arterially represent a major concern
and could account for the vast majority of the adverse
events reported. Accurate placement of the needle, use of a
non-particulate corticosteroid, live fluoroscopy, digital
subtraction angiography, and familiarisation of the operator
with contrast patterns on fluoroscopy should minimise
these risks. The available literature has several limitations
including incomplete documentation, unreported data and
inherent bias. Large registries and well-structured obser-
vational studies are needed to determine the true incidence
of adverse events and address the safety concerns.
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Key Points
Serious complications including damage to the
neural elements, stroke and death have been reported
with epidural corticosteroid injections (ESIs) but are
mostly anecdotal. Their true incidence is unknown,
but such outcomes seem to be rare.
Vascular penetration is possible, relatively more
frequent in the cervical segments and potentially
hazardous. Intravascular injection can be reduced by
use of injected contrast media.
The use of a blunt needle, live fluoroscopy, digital
subtraction angiography and the administration of a
small test dose initially could help reduce the adverse
effects.
Many complications can be avoided by a thorough
understanding of the anatomy, accurate placement of
the needle and familiarisation of the contrast patterns
on fluoroscopy.
More research must be performed regarding the
benefits versus risk, techniques and outcome of ESIs.
1 Introduction
Epidural corticosteroid injections (ESIs) have been used
for decades as a therapeutic modality in the management of
spinal pain syndromes attributed to disc pathology and
spinal stenosis. Although the exact pathophysiology of
these conditions remains obscure, it has been suggested
they occur through an ectopic ‘‘firing action potentials’’
mechanism in nerve roots derived from the mechanical
compression [1]. This mechanical compression could
stimulate a local inflammatory process, which forms the
rationale behind the administration of the corticosteroids.
This theory is further strengthened by findings suggesting
that the lavage of inflammatory mediators may reduce pain
and inflammation [2].
Epidural injections can be administered through a
transforaminal, interlaminar or caudal route. The inter-
laminar route is considered to be non-specific and the
injectate is free to spread within the posterior epidural
space with possible flow anteriorly, cephalad and caudally
[3]. This could be influenced by tissue fibrosis, scarring or
hypertrophy, which may occur in spinal pathology [4].
Transforaminal ESIs are more specific and selected nerves
can be targeted. ESI administered through this route could
in theory deposit a larger mass of corticosteroid close to the
pain generators at the ventral epidural space allowing a
greater degree of drug diffusion, so transforaminal ESI may
be more efficacious in alleviating patients’ pain [4].
However, several prospective randomised studies have
failed to demonstrate a statistically significant difference in
terms of pain reduction and functional score improvement
between the transforaminal and interlaminar approaches [5,
6]. In a recent systematic literature review of comparative
studies involving patients with lumbosacral radicular pain,
Chang-Chien et al. [5], suggested that both approaches are
equally effective and demonstrated only minor non-sig-
nificant differences between them. In contrast to the
interlaminar and transforaminal routes, caudal epidural
injections require relatively higher volumes of corticos-
teroids but are considered to be easier and safer and are
preferred in patients after spinal surgery.
The modality of imaging may influence the efficacy of
ESI. Currently, fluoroscopy, ultrasound and computed
tomography (CT) imaging have been used and their utili-
sation continues to increase. The choice amongst them
partly lies in personal preference but also on the availability
and prior training on the device. Limited evidence currently
exists in terms of the effectiveness and safety differences
between these techniques. For instance, a recent literature
review by Bui and Bogduk [7] concluded that CT-guided
lumbar transforaminal injection of corticosteroids is neither
more effective nor safer than the fluoroscopy-guided injec-
tions but that CT is associated with significantly higher
radiation doses than conventional fluoroscopy. Ultrasound
has gained popularity and maybe a safe alternative to the
other radiological imaging modalities [8].
2 Risk Versus Efficacy of Epidural Corticosteroid
Injections (ESIs)
Several authors have questioned the overall efficacy of ESIs
for the management of radicular pain [9–12]. In a systematic
review of the available literature in 2009 by Chou et al. [9],
ESIs were moderately effective for short-term symptom
relief in patients with low back pain but conferred no long-
term benefit. In a similar manuscript, Pinto et al. [11] con-
cluded that epidural corticosteroid injections offer only
short-term relief of leg pain and disability for patients with
sciatica. The authors questioned the clinical justification of
this procedure when comparing the benefits with the risks.
Furthermore, in a systematic review including data from the
Cochrane Central Register of Controlled Trials, Staal et al.
[12] concluded that there is insufficient evidence to support
the use of injection therapy in subacute and chronic low back
pain. These conclusions have been challenged by several
other trials and systematic reviews [13–18]. In patients with
lumbar radicular pain caused by contained disc herniations,
MacVicar et al. [16] suggested that lumbar transforaminal
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injection of corticosteroids is effective in reducing pain,
restoring function, reducing the need for other healthcare
modalities and avoiding surgery [16]. In line with these
deductions, Quraishi [18] concluded that in patients with
lumbar radiculopathy, ESIs result in an improvement in pain
but not disability. Friedly et al. [10] suggested that epidural
injection of glucocorticoids plus lidocaine offered minimal
or no short-term benefit as compared with epidural injection
of lidocaine in the treatment of lumbar spinal stenosis alone.
ESIs were found to have significant effect in relieving
chronic intractable pain of cervical origin, providing long-
term relief [14]. Some meta-analyses suggested that there is
good evidence for the effectiveness of cervical interlaminar
epidural injections in managing radiculitis secondary to disc
herniation and fair evidence in managing axial or discogenic
pain, pain of central spinal stenosis and pain of post-surgery
syndrome [15, 17]. The same authors concluded that the
evidence is poor for cervical transforaminal epidural injec-
tions. It should be mentioned, however, that several of these
studies have been criticised for flaws and deficiencies,
adding further overall confusion.
In addition to the controversy surrounding the efficacy
of ESIs, some authors have raised concerns regarding
potential adverse events. On 23 April 2014 the US Food
and Drug Administration (FDA) issued a warning to the
medical community covering the potential risks of these
injections [19]. The warning states that ‘‘injection of cor-
ticosteroids into the epidural space of the spine may result
in rare but serious adverse events, including loss of vision,
stroke, paralysis, and death’’.
This systematic review aims to scrutinise the available
literature, present the available data and documentation
from several authors, and analyse the risks involved with
the ESIs in the cervical and lumbar spine.
3 Methods
This review was carried out in accordance to the PRISMA
guidelines [20]. Data were documented according to a
standardised protocol, where objectives and inclusion cri-
teria were specified in detail.
Publications from the last 20 years (September 1994 to
September 2014) were considered for further analysis.
Studies selected were original articles, in the English lan-
guage, publishing results on complications related to the
technique used for the ESIs. Only cervical and lumbar ESIs
were included and the studies had to specify the approach
used for injection. All studies that did not fulfil these eli-
gibility criteria were excluded from further analysis.
Studies were identified by searching the following
resources/databases to retrieve all available relevant arti-
cles: PubMed MEDLINE, Ovid MEDLINE, EMBASE,
Scopus, Google Scholar and the Cochrane Library. The
terms used for the search included ‘epidural’, ‘injection’,
‘corticosteroid’ and ‘steroid’ both isolated or in combina-
tion with specific words including ‘transforaminal’, ‘in-
terlaminar’, ‘adverse events’, ‘complication’ and ‘side
effect’. The identified articles and their bibliographies
including any relevant reviews were manually searched for
additional potential eligible studies.
Two of the authors (Ippokratis Pountos and Gavin
Walters) of this systematic review performed 208 the
assessment, in an independent, unblinded and standardised
manner. Most citations were excluded on the basis of
information provided by their respective title or abstract. In
any other case, the complete manuscript was obtained and
scrutinised by two reviewers.
4 Results
Of 3255 papers initially identified, 162 met the inclusion
criteria (Fig. 1). This included 58 studies, of which 38
recorded complications while the remaining 20 state that
217 no complications were encountered [21–78]. 101 case
reports were also found [79–179].
4.1 Interlaminar Cervical ESIs
The review of the available literature identified 11 manu-
scripts presenting complications following interlaminar
cervical ESIs (Table 1) [21, 22, 24, 26, 28–34]. One
Fig. 1 Flowchart of study selection
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Table 1 Complications reported with interlaminar cervical epidural corticosteroid injections
Study, year Design Pts Medications Imaging Complications








FL Overall 16.8 %:
23 Increased neck pain (6.7 %)
16 Non-positional headaches
(4.6 %)
6 Insomnia (1.7 %)
6 Vasovagal reactions (1.7 %)
5 Facial flushing (1.5 %)
1 Pyrexia (0.3 %)
1 Dural puncture (0.3 %)




4389 Injections NA NA 3 Dural punctures (0.07 %)
17 Vagal symptoms (0.4 %)






29 pts, 65 injections NA FL 16.9 % headaches
21.5 % insomnia, flushing of the
face, temperature
6.2 % of increased pain




76 pts, 76 injections Triamcinolone acetonide
40 mg
FL 2 Dural punctures (2.6 %)









2376 Injections NA FL 100 Intravascular placement of
needle (4.2 %)
24 Dural puncture (1 %)
6 Transient nerve root irritation
(0.25 %)
5 Transient spinal cord irritation
(0.21 %)
16 Profuse bleeding (0.7 %)
1 Vasovagal (0.04 %)
2 Facial flushing (0.08 %)




*127 Injections Dexamethasone sodium
phosphate 10 mg
FL 1 Vasovagal and syncope
(0.8 %)





65 pts NA FL 1 Vasovagal (1.54 %)




RCT 120 pts, 654 injections Betamethasone 6 mg
(n = 60)




5 Nerve root irritations (0.76 %)
1 Pain lasting 1 week (0.15 %)
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manuscript that reports no complications has also been
identified but only includes 14 interlaminar cervical ESIs
[23].
Based on the available studies, the incidence of dural
puncture ranged between 0.07 and 2.6 %. Vasovagal
reactions ranged between 0.04 and 1.7 %. In a prospective
study including 2376 injections, Manchikanti et al. [34]
reported 100 cases where intravascular placement of the
needle occurred [34]. However, complications that could
potentially be correlated with inadvertent intravascular
injection of corticosteroids were low and included 11 cases
of transient nerve root or spinal cord irritation, one vaso-
vagal event and two cases of facial flushing. In a retro-
spective analysis of the results of 345 C6–7 or C7–T1
injections, Botwin et al. [22] reported an overall incidence
of complications of 16.8 %. A large proportion of these
adverse events were related to an increase of neck pain,
headache, insomnia and vasovagal reactions.
4.2 Transforaminal Cervical ESIs
There are limited studies analysing the complications from
this approach. Furman et al. [25] presented 504 cervical
(C3–C8) transforaminal ESIs performed on 337 patients
[25]. They reported identification of 98 intravascular
injections that did not result in any adverse effects. Simi-
larly, other authors have reported no complications [27, 31,
37–39]. In a retrospective review of 1579 injections, Derby
et al. [24] reported two cases of aggravated radicular pain,
two cases of prolonged paraesthesias and the development
of skin rash in one patient. In another study including 43
ESIs with prednisolone, 19 % of patients experienced
minor neurovegetative manifestations [43]. Scanlon et al.
[41] conducted an anonymous survey asking the US
physician members of the American Pain Society about
their experience with regards to serious complications
following cervical transforaminal epidural corticosteroid
injections (TESIs) [41]. From the 287 replies, 78 compli-
cations were reported, among which there were 30 brain or
spinal cord infarcts and 24 neurologic complications
including death of unsuspected aetiology (n = 5), high
spinal anaesthesia (n = 3), transient ischaemic attacks
(n = 3), and spinal cord or brainstem oedema (n = 3).
Overall, the survey revealed 13 cases with a fatal outcome
[41].
4.3 Interlaminar Lumbar ESIs
The literature search found 11 studies that present adverse
effects following interlaminar lumbar ESIs (Table 2) [34–
36, 40, 42, 44, 45, 47–52]. In addition, four studies that
involve more than 250 patients have reported no adverse
events following interlaminar lumbar epidural ESIs [46,
54, 55, 60]. In a prospective cohort study including 1450
injections, Manchikanti et al. [34] reported an incidence of
0.8 % for dural puncture and profuse bleeding following
the injection [34]. A prospective, randomised blinded study
including 106 patients has reported a rather high number of
minor adverse effects [35]. In particular, 26 % of the
patients experienced discomfort and pain at the injection
site, 18 % had non-positional headache and 10 % suffered
from nausea after the injection. In an analysis of 6631
interlaminar lumbar ESIs, Huang et al. [48] found 42 cases
of inadvertent lumbar facet joint injection [48]. In 31 cases
the physician recognised the lumbar facet joint injection. A
similar study design reported by Candido et al. [46]
reported the incidence of intradiscal injection to be one in
4723 [46].
4.4 Transforaminal Lumbar ESIs
Fourteen studies were identified that presented adverse
effects following transforaminal ESIs (Table 3) [34, 50,
53, 56–59, 61, 63, 65–69]. In contrast, no adverse events
were presented by a number of other authors [25, 62, 70–
78]. McGrath et al. [59] retrospectively reviewed the
charts of patients receiving ESIs over a 7-year period
[59]. Of the 3964 injections included, only minor com-
plications were reported in 84 injections. The most
common complication reported was increased pain,
which was encountered in half of the patients. Two
prospective studies analysing a large number of trans-
foraminal lumbar ESIs reported an incidence of
intravascular penetration of between 7.4 and 7.9 % [34,
Table 1 continued
Study, year Design Pts Medications Imaging Complications
Manchikanti et al.,
2014 [32]
RCT 120 pts, 688 injections Betamethasone 6 mg
(n = 60)




3 Nerve root irritations (0.76 %)
1 Pain lasting 1 week (0.15 %)
CT computed tomography, FL fluoroscopy, NA not available, pts patients, RCT randomised controlled trial
Safety of Epidural Corticosteroid Injections 23
57]. The main difference was an 8.7 % rate of vasovagal
episodes reported by Karaman et al. [57]. A similar rate
was reported by Ploumis et al. [61], although only 20
patients were included in that study. Hong et al. [56]
identified six intradiscal injections among 249 trans-
foraminal ESIs, which represents an incidence of 2.4 %
[56]. A lower incidence of one in 402 injections was
reported by Candido et al. [46], although this was tenfold
higher than after interlaminar ESI [46].
4.5 Adverse Event Case Reports According
to the Approach Used
A large number of case reports presenting rare adverse
events following ESIs exist (Fig. 2) [79–179]. The avail-
able literature has described deaths following ESIs [89, 93,
97]. Reviewing the available case reports, the most com-
mon and devastating complication was infarction of the
spinal cord, cerebellum, brain and brainstem [97, 141].
Table 2 Complications reported with interlaminar lumbar epidural corticosteroid injections












RCT 87 pts, 87
injections
Triamcinolone 10 mg CT 1.9–3.6 % headache
Valat et al., 2003
[42]
RCT 39 pts, 117
injections
Prednisolone acetate 50 mg BL 2 Headache
Arden et al.,
2005 [44]
RCT 115 pts, 3
injections
each










Dexamethasone 16 mg FL 42 Facial flushing (28 %)






Dexamethasone phosphate 15 mg or
methylprednisolone acetate 80 mg
FL 1 Intrathecal injection
Manchikanti







Betamethasone 1 mL (n = 60) FL 3 Subarachnoid punctures
(1.4 %)
Manchikanti





NA FL 7 Intravascular placement of
needle (0.5 %)
4 Transient nerve root
irritation (0.28 %)
11 Dural punctures (0.8 %)
11 Profuse bleeding (0.8 %)
4 Local haematoma
(0.28 %)
1 Headache (0.07 %)



























Methylprednisolone acetate 80 mg FL (n = 56),
US
(n = 56)
15 Dizziness or pain at
injection site or facial
flushing
1 Intrathecal injection
BL blind, CT computed tomography, FL fluoroscopy, NA not available, pts patients, RCT randomised controlled trial, US ultrasound
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Infarctions could occur due to damage to the blood vessels,
or either to vasospasm or an emboli from particulate matter
associated with the corticosteroid injection. Damage to the
blood vessels could result in haematomas, and subdural and
epidural haematomas have been reported [124, 135, 144,
146, 155, 162, 164]. Permanent paralysis can occur fol-
lowing such haematomas [145]. Direct damage to the
spinal cord by trauma or direct injection of ESI medica-
tions into the cervical spinal cord has been also docu-
mented [140, 148, 160, 173]. Such a complication can
Table 3 Complications reported with transforaminal lumbar epidural corticosteroid injections










FL 10 Non-positional headaches (3.1 %)
8 Increased back pain (2.4 %)
2 Increased leg pain (0.6 %)
4 Facial flushing (1.2 %)
1 Vasovagal reaction (0.3 %)
1 Increased blood sugar (258 mg/dL) in an
insulin-dependent patient with diabetes
mellitus (0.3 %)








Dexamethasone 4, 8 or 12 mg FL 1 Pain at injection site
5 Vascular uptake








Triamcinolone acetonide FL 97 Vascular penetration (7.4 %)
8.7 % vasovagal episodes
5 Transient erectile dysfunction (0.9 %)








NA FL 42 Increased pain
6 Numbness
9 Pain at injection site
Manchikanti





NA FL 104 Intravascular placement of needle (7.9 %)
16 Transient nerve root irritation (4.6 %)
8 Profuse bleeding (1 %)
1 Vasovagal (0.08 %)





153 pts Methylprednisolone 40 mg FL 2 Discitis
Wewalka et al.,
2012 [69]
Cohort study 37 pts, 65
injections
Triamcinolone 40 mg CT 3 Transient weakness
14 Increased low back pain
2 Low blood pressure post-injection
Koh et al., 2013
[65]







Triamcinalone 40 mg FL 2 Vasovagal episodes






Dexamethasone 5 mg and
mepivacaine 3 mL
FL 6 Intradiscal injection
Manchikanti
et al., 2014 [67]
RCT 120 pts, 601
injections
Betamethasone 3 mg FL 28 Intravascular infiltrations (4.6 %)
9 Nerve root irritations (1.5 %)
Kraiwattanapong












Betamethasone 9 mg FL 2 Vasovagal episodes (10 %)
Tauheed et al.,
2014 [68]
RCT 60 pts Methylprednisolone 60 mg FL 3 Transient paraesthesia of nerve distribution
CT computed tomography, FL fluoroscopy, NA not available, pts patients, RCT randomised controlled trial
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occur with an absence of pain being reported by the patient
when the spinal cord structures were punctured [156].
Subdural and intrathecal spread or diffusion of the injected
mixture of corticosteroids, anaesthetic and contrast dye
could result in cauda equina and conus medularis syn-
dromes, arachnoiditis, meningitis and temporary respira-
tory depression [139, 148, 153, 171]. Intracranial subdural
haematoma after accidental dural puncture has also been
presented [142]. Furthermore, cases of pneumocephalus,
pneumorrhachis and cerebrospinal fluid (CSF) leak can
occur [90, 94, 95, 147, 151, 153, 170].
Infections and abscesses have been also reported fol-
lowing ESI [108–114, 117–127, 130, 132, 133, 164]. With
the exception of a fungal infection outbreak in the USA in
2012, infection rates are considered rare [109]. Infection
rates vary following an epidural injection, but, on average,
are reported to be one in 60,000–100,000 epidural injec-
tions [112]. The documented outbreak in 2012 was possi-
bly caused by a contaminated glucocorticoid product used
for epidural and paraspinal injection [108, 109]. In single
case reports, cases of meningitis, vertebral osteomyelitis,
and spinal and paraspinal abscesses have been reported that
are caused by microorganisms including Aspergillus spp.,
Staphylococcus aureus and methicillin-resistant S. aureus
[111, 113, 126]. Patients’ skin flora has been proposed to
be the most common source of infection [125].
Blindness after ESI has been reported multiple times
[82–84, 86, 87, 154, 167]. It has been hypothesised that this
complication is caused by an abrupt rise in the CSF pres-
sure caused by the volume of the injected pharmaceutical
agents. In the cervical spine, this complication can be the
result of the administration of radio contrast agents
administered in the intracranial vasculature [84]. The
patient’s vision returned to normal within 1 year of follow-
up in some studies [82, 83], but permanent visual impair-
ment in patients’ vision was reported by some authors [84,
86, 87, 167].
Vaginal bleeding has been reported as a potential
complication of ESI [99, 101]. Suh-Burgmann et al. [116]
have retrospectively reviewed 8166 ESI procedures and
reported an incidence of 2.5 % (n = 201; 197 patients) for
abnormal vaginal bleeding [116]. Of these women, 70 %
were premenopausal and 30 % were postmenopausal.
Suppression of the hypothalamic–pituitary–ovarian axis
causing anovulatory cycles has been hypothesised to be the
mechanism for this adverse effect [115].
Case reports have also presented other complications
including iatrogenic Cushing’s syndrome [131, 166], per-
sistent hiccups [128, 152], convulsions [129], reversible
posterior leukoencephalopathy syndrome [82], epidural
granuloma formation [150], subdural block [157], Brown–
Se´quard syndrome [159], herpes zoster outbreak [165],
Cervical Interlaminar 
Spinal Cord Injury 172
Cervical Transforaminal  
Death 89,93,97,177,178
Stroke 85,97,178












Spinal Cord Infarcon  
79,100,102,103,105,107
Spinal Cord Injury 80,81
Fig. 2 Reported major complications and approach used
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steroid myopathy [166] and corticosteroid-induced psy-
chosis [137] following ESI. Spinal epidural lipomatosis is a
rare condition of adipose tissue hypertrophy in the epidural
space and has been reported to occur after ESI [138, 143,
161]. In addition, cardiopulmonary arrest following ESI
and anaphylaxis and other adverse events due to the
epidural corticosteroid compounds can occur [134, 136,
149, 169, 175]. Complex regional pain syndrome and
development of neuropathic pain following ESI have also
occurred [158, 163].
5 Discussion
ESIs have been used for more than 60 years since Lievre
et al. [180] reported the use of epidural hydrocortisone in a
series of 20 patients. Over the years, their use has expanded
significantly. In Medicare beneficiaries in the USA, the
number of epidural injections has increased by 106.3 % in
the decade between 1997 and 2006 [181]. Currently, ESIs
are the most common intervention performed for the
management of chronic low back pain in the USA [182].
Nevertheless, their clinical need and effectiveness has been
questioned by several studies [10]. Indications for ESI are
not robust and the outcome could not be correlated with the
extent of the underlying pathology, e.g. the degree of
lumbar spinal stenosis, but could be determined by factors
such as age, sex and the preceding opioid use [183–185].
Collectively, this systematic review contains data from
more than 100,000 ESIs reported in prospective or retro-
spective studies. The reported complications were minor in
the vast majority. Major events have been reported anec-
dotally and it is impossible to comment on their true
incidence based on the available results in the literature.
Overall, the potential causes of adverse events could be
categorised into three distinct categories: (1) direct damage
to the blood vessels or adjacent anatomical structures
during the procedure; (2) intravascular administration of
the injectate; and (3) a local or systemic reaction including
bacterial contamination.
Direct damage to the blood vessels or adjacent structure
is an inherent risk for any injection, including ESIs. Direct
damage to the spinal cord by the needle and the injection of
corticosteroids into the cervical spinal cord has been also
documented in a very limited number of case reports.
Clinically significant haematomas derived from piercing or
damage to the blood vessels can occur and the reported
incidence for all epidurals is less than one in 150,000. This
complication is increased in patients with coagulopathy
and patients on anticoagulant medications [186–188].
Inadvertent dural punctures can occur after ESIs and CSF
flashback is pathognomonic of this complication. Other
complications, including intracranial subdural haematoma
after accidental dural puncture and cases of pneumo-
cephalus, pneumorrhachis and CSF leak, have been pre-
sented in case reports [90, 94, 95, 98].
Intravascular injection of the corticosteroids, carrier and/
or the local anaesthetic could account for the large majority
of the serious adverse effects. The reported incidence of
inadvertent intravascular injection with fluoroscopically
guided TESI is reported to range from 9 % to as high as
32.8 % [25, 189–192]. This incidence is related to the level
at which the injection is performed. Furman et al. [25, 189]
reported an incidence of fluoroscopically confirmed
intravascular penetration of 19.4 % for cervical TESIs,
8.1 % for lumbar TESIs and 21.3 % for TESIs at the S1
level. In addition, Sullivan et al. [192] suggested that
intravascular uptake is twice as likely to occur in patients
over rather than under 50 years of age [192]. Vascular
embolic events from intra-arterial injection of particulate
corticosteroids have been found to account for serious
complications including spinal cord infarction, paraplegia
and death [93, 100, 102, 103, 105]. Houten et al. [102]
presented three cases of paraplegia which ensued suddenly
after instillation of the corticosteroid solution in the artery of
Adamkiewicz. Similar cases have been reported by others
[34]. It should be mentioned that intra-articular injections
pose a higher degree of danger, while venous uptake has
been considered benign [193, 194]. In terms of the injectate,
medium-sized particles between 51 and 1000 lm have the
potential to enter and occlude a blood vessel [195]. Smaller
particles (10–50 lm) may still be able to occlude capillaries
[195]. Irrespective of the size, it has been suggested that
when corticosteroid particles enter a blood vessel they could
coalesce and precipitate, forming larger particles [195].
Non-particulate corticosteroids are soluble and should not
cause embolic infarction. The injection of the particulate
corticosteroid methylprednisolone into the vertebral artery
of four pigs resulted in permanent loss of consciousness,
while the animals receiving dexamethasone and pred-
nisolone recovered fully [194]. Dawley et al. [193]
demonstrated that methylprednisolone and its non-particu-
late carrier can produce significant injury to the blood–brain
barrier when injected intra-arterially. The authors also sug-
gested that in addition to the cerebral microvasculature
occlusion by the particulate corticosteroids, damage can
occur via toxicity of the carrier or the corticosteroid. Based
on several observations that failed to highlight any differ-
ence in the efficacy of particulate and non-particulate cor-
ticosteroids, we would recommend the use of soluble non-
particulant agents [196–198].
The local anaesthetic, corticosteroid or carrier can cause
local and systemic reactions. Blockage of the neural ele-
ments by the local anaesthetic can occur. A transient
blockage of the neural conduction is expected; however,
the reported central canal, conus medularis and cauda
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equina syndromes must have an underlying cause, i.e.
hematoma, infarct, etc. Transient systemic reactions
including headaches, vasovagal reactions and facial flush-
ing have been reported; these reactions occurred shortly
after the ESI and could represent a reaction to the injected
anaesthetic agents and/or corticosteroids. It is rather
unclear whether ESIs pose a long-term risk of certain
conditions and whether a cumulative effect of prolonged
exposure exists. If that is true, epidural corticosteroids
could have similar systemic effects to that of long-term
corticosteroids administered through other routes. For
instance, a significant number of the patients with chronic
back pain conditions are treated with repeated injections
over prolonged period of time. Corticosteroids are known
to interfere with calcium homeostasis, reducing bone for-
mation and increasing bone breakdown. Osteoporosis and
an increased fracture risk could theoretically occur; how-
ever, the available literature does not support this theory.
Manchikanti et al. [199] prospectively evaluated 100
patients receiving epidural injections and reported no
change in bone mineral density. Insulin resistance is
another adverse effect associated with corticosteroid
administration; however, studies looking specifically at
patients receiving ESIs did not find any changes in the
fasting glucose levels [200, 201]. Hypothalamic–pituitary–
adrenal axis suppression has been demonstrated to occur
after ESIs [200, 202]. Maillefert et al. [200] showed that
following ESI with dexamethasone a profound decrease in
the serum levels of adrenocorticotropic hormone (ACTH)
occurs. These levels of ACTH returned to normal 3 weeks
after the injection [200]. Hypertension can also occur fol-
lowing ESIs; a mean systolic blood pressure increase of
5 mmHg has been previously reported following ESIs
[201]. Finally, corticosteroid administration represents a
risk factor for wound complications postoperatively and
poses an increased risk for infections [203]. ESIs are fre-
quently performed prior to spinal surgery, either as a dis-
gnostic tool or for pain management, but their contribution
to complications of such procedures is currently unknown.
Severe infections are rare after spinal injections and
have an incidence of 0.1–0.01 % [188]. The only exception
is a fungal infection outbreak in the USA in 2012.
According to the Centers for Disease Control and
Prevention, 25 deaths due to epidural corticosteroid-related
meningitis (many due to Aspergillosis) were identified: 337
patients were affected in 18 US states and 14,000 patients
were probably exposed to contaminated corticosteroids
[186].
In the authors’ opinion, several recommendations can be
made with the aim of minimise the incidence of major
complications after ESIs. First, ESIs should be performed
under fluoroscopic guidance and the needle position should
be confirmed in at least two planes, typically
anteroposterior and either an oblique or lateral plane.
Intravascular penetration has been the primary concern
related to ESIs. Aspiration prior to the injection is specific
but not sensitive at detecting intravascular needle place-
ment, being unable to produce a flashback of blood in 74 %
of cases in which the needle was ultimately determined to
be intravascular [192]. Injection of contrast media is rec-
ommended and operators must be able to distinguish
between intravascular, epidural and subdural contrast flow
patterns. The use of a blunt needle and the suggestion that a
small ‘test’ dose of the medication should be inject initially
has been proposed [204–207]. Fluoroscopy can detect
unintentional vascular injections [208]. Dynamic live flu-
oroscopy was found to perform better than static inter-
mittent fluoroscopy, which was found to miss 57 % of the
intravascular injections [208]. Digital subtraction angiog-
raphy can be used as a radiologic adjunct to identify vas-
cular compromise during the injection. However, in a case
report by Chang et al. [80], an anaesthetic test dose and
digital subtraction angiography performed twice did not
prevent a catastrophic spinal cord infarction and the
resultant paraplegia. It is under debate whether the trans-
foraminal route poses a higher risk of serious complica-
tions when performed by an experience physician. Given
the lack of evidence, one could argue that it is reasonable to
consider the transforaminal approach only when the inter-
laminar route has failed. Finally, informed consent should
be taken and the patient should be aware of the potential
risk and benefits of this procedure.
The survey of cervical injections conducted by Scanlon
et al. [41] is the only manuscript that presents a high number
of serious and fatal cases. Possible mechanisms explaining
these events include the intra-arterial injection of particulate
corticosteroid or trauma causing embolisation to the distal
basilar or vertebral arteries. Despite the fact that the study
presents the extreme end of potential complications, it is
unclear what the true incidence of these events is. As pre-
viously mentioned, it would be of enormous educational
interest to have further details regarding these events, espe-
cially details of the technique and imaging used aswell as the
training and experience of the physician [209].
The warning issued by the FDA regarding ESIs merits
further discussion and analysis, and the use of corticos-
teroids for injections in the epidural space for spinal pain
syndromes is not FDA approved. The FDA mentions that,
despite their use, the effectiveness of ESIs has been chal-
lenged and could potentially result in serious adverse
events including death, stroke and paralysis. In support of
these arguments, the FDA has published several case
reports. Major adverse events can occur with ESIs, but
such events are rare, their true incidence is unknown and
they have only been presented in case reports. For instance,
none of the studies included in Tables 1, 2 and 3 presents
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such major devastating complications. Thus, several
authors have criticised the FDA’s warning statement as
inaccurate. Of note is Manchikanti et al. conclusion stating
that the FDA’s warning is an additional burden on patient
access to pain-relieving treatments [210]. Should the
FDA’s warning letter be replaced by an evidence-based
educational guidance to safeguard the best clinical
practice?
Several limitations can be found in the available litera-
ture. A large proportion of the available case reports and
studies provide insufficient documentation, i.e. the
approach used for ESI, symptom duration, volume injected
or even the number of injections. In addition, the majority
of the studies report adverse effects incidentally as their
main aim is to report the efficacy of the injections. Fur-
thermore, the available studies were heterogeneous with
regards to the outcome measures, and in several manu-
scripts the surgical technique, corticosteroid dosage and the
addition of other medications are not reported. It is of note
that many studies did not look at or record the complica-
tions or adverse effects of corticosteroid exposure but
present results from several pain and functional scores.
Therefore, it is possible that both the short- and long-term
adverse effects of corticosteroid exposure remain unre-
ported. As previously highlighted, there is a risk of bias.
6 Conclusions
ESIs are relatively safe; however, although major compli-
cations of ESIs have been reported, their true incidence
remains obscure. Vascular penetration and administration
of pharmaceutical agents intra-arterially could account for
a large proportion of the adverse events reported. With
accurate placement of the needle, use of non-particulate
corticosteroids, live fluoroscopy, digital subtraction
angiography and familiarisation of the contrast patterns on
fluoroscopy these risks should be minimised. Further
research is required to shed more light on the best clinical
practice for the use of ESIs and the true incidence of
complications relating to them.
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